{"id":2054,"date":"2024-06-21T14:02:38","date_gmt":"2024-06-21T14:02:38","guid":{"rendered":"https:\/\/stage.hallwang2.smithberlin.com\/?post_type=testi&p=2054"},"modified":"2025-01-10T17:29:15","modified_gmt":"2025-01-10T17:29:15","slug":"bruce-and-chris","status":"publish","type":"testi","link":"https:\/\/www.hallwang-clinic.com\/de_DE\/experience\/bruce-and-chris\/","title":{"rendered":"Bruce and Chris"},"content":{"rendered":"\n

We received good news for one of our patients and are happy to share these with you on Bruce\u2019s behalf.<\/p>\n\n\n\n

\n

Bruce was diagnosed in May 2013 with stage IIIC malignant melanoma of his right foot with a micrometastastic disease in 1\/7 lymph nodes from the right popliteal and groin area.<\/p>\n<\/blockquote>\n\n\n\n

In July of the same year, a dissection took place and Bruce decided to not receive the adjuvant interferon treatment, before he underwent a new biopsy in October 2013, confirming progressive disease. A few of the skin metastases were resected, and he underwent hyperthermic limb perfusion therapy. Unfortunately, in February 2014, the disease progressed even further. Analysis of Bruce\u2019s tumor biopsy showed a BRAF-V600E mutation. So he started on the BRAF\/MEK inhibitor dabrafenib and trametinib, which he took for nearly a year and a half. In July 2015, a restaging scan was unfortunately suggestive of disease progression, so Bruce started checkpoint-antibody treatment with nivolumab. Unfortunately, three months under this treatment, Bruce developed a grade III colitis (inflammation of the colon), that needed to be treated with corticosteroids. Disappointingly, Bruce was no longer able to continue the treatment. Once he fully recovered, he started on vemurafenib and cobimetinib (a different BRAF\/MEK-inhibitor) treatment in January 2016, and searched for further options – and contacted our team at the Hallwang clinic.<\/p>\n\n\n\n

At the Hallwang Clinic, we started with a thorough diagnostic approach and first screened Bruce\u2019s tumor tissue for tumor associated antigens in order to identify potential therapeutic targets. Bruce\u2019s tumor tissue was tested positive for expression of Melan-A and Survivin. When Bruce visited us in April 2016 for the first time, we discussed a treatment with a so called trifunctional antibody approach \u2013 targeting anti-GD2. GD2 is a marker which is expressed on tumors of neuroectodermal origin, and thus often found in melanoma patients, as well as in patients with neuroblastoma and different kinds of sarcomas. To evaluate Bruce\u2019s eligibility for this treatment, a blood analysis for circulating-GD2 positive cells was performed, showing that his tumor was highly GD2-positive (3+).<\/p>\n\n\n\n

Having completed all diagnostic steps and after careful evaluation, Bruce started on a combined immunotherapeutic approach targeting TAA\u2019s in combination with anti-GD2 treatment and the BRAF\/MEK-inhibitor. Since then, Bruce is visiting us every three months for three days, continuing his treatment strategy. Bruce has now achieved and maintained a \u201cno evidence of disease\u201c status (NED) for about 2 and 1\/2 years now, and 5 years since diagnosis!! We are so happy for you, Bruce! Continue on this path!<\/p>\n\n\n\n

<\/div>\n\n\n\n

Beachten Sie bitte, dass es sich bei den Aussagen um Originalaussagen handelt und diese von den individuellen Patienten selbst verfasst wurden. Eine \u00dcbersetzung dieser Originalaussagen ist daher nicht m\u00f6glich, so dass nur die Originale in der von den Patienten verwendeten Sprache zur Verf\u00fcgung stehen.<\/p>\n\n\n\n

Bitte beachten Sie, dass wir aus datenschutzrechtlichen Gr\u00fcnden keine Aktualisierungen zu fr\u00fcheren Testimonials bereitstellen k\u00f6nnen, die auf Wunsch unserer Patienten ver\u00f6ffentlicht wurden. Bitte verstehen Sie die Erfahrungsberichte nicht als objektive und vollst\u00e4ndige Zusammenfassung der individuellen Behandlung. In vielen F\u00e4llen verwenden die Patienten Testimonials, um unserem Team ihren Dank auszudr\u00fccken, da wir sie in einer sehr schwierigen Situation unterst\u00fctzt haben \u2013 unabh\u00e4ngig von ihrem Behandlungsansprechen. Auch im Todesfall eines Patienten k\u00f6nnen wir aus datenschutzrechtlichen Gr\u00fcnden dies nicht immer unter dem jeweiligen Testimonial ver\u00f6ffentlichen. Wenn Sie selbst der Patient oder ein gesetzlicher Vertreter sind und ein Testimonial entfernen lassen m\u00f6chten, wenden Sie sich bitte an unsere Administration: info@hallwang-clinic.com<\/p>\n","protected":false},"featured_media":5428,"template":"","disease_type":[22],"class_list":["post-2054","testi","type-testi","status-publish","has-post-thumbnail","hentry","disease_type-hautkrebs","de_DE","teaser-view"],"_links":{"self":[{"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/testi\/2054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/testi"}],"about":[{"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/types\/testi"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/media\/5428"}],"wp:attachment":[{"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/media?parent=2054"}],"wp:term":[{"taxonomy":"disease_type","embeddable":true,"href":"https:\/\/www.hallwang-clinic.com\/wp-json\/wp\/v2\/disease_type?post=2054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}